A3 adenosine receptors modulate hypoxia-inducible factor-1α expression in human A375 melanoma cells

Neoplasia

Volumn 7, Issue 10, 2005, Pages 894-903

  Merighi, Stefania ^a   Benini, Annalisa ^a   Mirandola, Prisco ^b   Gessi, Stefania ^a   Varani, Katia ^a   Leung, Edward ^c   MacLennan, Stephen ^c   Baraldi, Pier Giovanni ^a   Borea, Pier Andrea ^a,d  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c King Pharmaceutical R and D   (United States)

^d Department of Clinical and Experimental Medicine Pharmacology Unit ^*  (Italy)

Author keywords

A3 receptors; Adenosine; HIF 1 ; Hypoxia; Tumor cells

Indexed keywords

ADENOSINE; ADENOSINE A3 RECEPTOR; ANGIOPOIETIN 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; OXYGEN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL SURFACE; HUMAN; HUMAN CELL; HYPOXIA; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; ANOXIA; BIOSYNTHESIS; CHEMISTRY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; MELANOMA; METABOLISM; NEOPLASM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TIME; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

ADENOSINE; ANGIOPOIETIN-2; ANOXIA; BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS; OXYGEN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, ADENOSINE A3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 33644877968     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05334     Document Type: Article

References (63)

1. Linden J (2001). Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41, 775-787.
2. 2A adenosine receptor-mediated mechanisms of tissue protection. Annu Rev Immunol 22, 657-682.
3. Fredholm BB (2003). Adenosine receptors as targets for drug development. Drug News Perspect 16, 283-289.
4. Hockel M and Vaupel P (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93, 266-276.
5. Blay J, White TD, and Hoskin DW (1997). The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57, 2602-2605.
6. Spychala J (2000). Tumor-promoting functions of adenosine. Pharmacol Ther 87, 161-173.
7. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, and Borea PA (2003). A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100, 31-48.
8. Ralevic V and Burnstock G (1998). Receptors for purines and pyrimidines. Pharmacol Rev 50, 413-492.
9. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, and Linden J (2001). International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53, 527-552.
10. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, and Borea PA (2002). Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119, 923-933.
11. Merighi S, Baraldi PG, Gessi S, Iannotta V, Klotz KN, Leung E, Mirandola P, Tabrizi MA, Varani K, and Borea PA (2003). Adenosine receptors and human melanoma. Drug Dev Res 58, 377-385.
12. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 59, 76-82.
13. 3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 278, 42121-42130.
14. 3 adenosine receptors in Jurkat T cells. Br J Pharmacol 134, 116-126.
15. Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, and Borea PA (2001). Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 134, 1215-1226.
16. Suh BC, Kim TD, Lee JU, Seong JK, and Kim KT (2001). Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Br J Pharmacol 134, 132-142.
17. 3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol 61, 415-424.
18. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 10, 5895-5901.
19. 3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10, 4472-4479.
20. 2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol 164, 1887-1892.
21. Hasko G and Cronstein BN (2004). Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25, 33-39.
22. 2B angiogenic phenotype. Hypertension 44, 649-654.
23. 3 adenosine receptors. Circ Res 92, 485-492.
24. 2B receptors in angiogenic factor regulation. Circ Res 90, 531-538.
25. 2A receptor agonists and endotoxin. Am J Pathol 160, 2231-2244.
26. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732.
27. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54.
28. Wiener CM, Booth G, and Semenza GL (1996). In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 225, 485-488.
29. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, and Caro J (2002). Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 277, 6183-6187.
30. Semenza GL (2000). HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88, 1474-1480.
31. Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, and Hedley DW (2002). Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 53, 854-861.
32. Janssen HL, Haustermans KM, Sprong D, Blommestijn G, Hofland I, Hoebers FJ, Blijweert E, Raleigh JA, Semenza GL, Varia MA, et al. (2002). HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 54, 1537-1549.
33. Hopfl G, Ogunshola O, and Gassmann M (2004). HIFs and tumors - causes and consequences. Am J Physiol Regul Integr Comp Physiol 286, R608-623.
34. Welsh SJ and Powis G (2003). Hypoxia-inducible factor as a cancer drug target. Curr Cancer Drug Targets 3, 391-405.
35. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW (1999). Over-expression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59, 5830-5835.
36. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al. (1998). HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490.
37. Jiang BH, Agani F, Passaniti A, and Semenza GL (1997). V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase: 1. Involvement of HIF-1 in tumor progression. Cancer Res 57, 5328-5335.
38. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94, 8104-8109.
39. Ryan HE, Lo J, and Johnson RS (1998). HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17, 3005-3015.
40. Kung AL, Wang S, Klco JM, Kaelin WG, and Livingston DM (2000). Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6, 1335-1340.
41. Ratcliffe PJ, Pugh CW, and Maxwell PH (2000). Targeting tumors through the HIF system. Nat Med 6, 1315-1316.
42. + T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 104, 2418-2424.
43. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, and Eckardt KU (2004). Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18, 1462-1464.
44. 2B adenosine receptor antagonists. J Med Chem 47, 1434-1447.
45. 3 adenosine receptors. Mol Pharmacol 57, 968-975.
46. Klotz KN (2000). Adenosine receptors and their ligands. Naunyn-Schmiedeberg's Arch Pharmacol 362, 382-391.
47. Merighi S, Mirandola P, Varani K, Gessi S, Capitani S, Leung E, Baraldi PG, Tabrizi MA, and Borea PA (2003). Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. Biochem Pharmacol 66, 739-748.
48. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273, 18623-18632.
49. Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ, and Jakubowski JA (1996). p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271, 27723-27729.
50. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95, 7987-7992.
51. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL (2002). Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277, 38205-38211.
52. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, and Semenza GL (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60, 1541-1545.
53. Semenza GL (2002). Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64, 993-998.
54. 3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58, 477-482.
55. 3 receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 62, 1137-1146.
56. Schulte G and Fredholm BB (2003). Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15, 813-827.
57. 3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase (PI3K)/AKT-dependent inhibition of the extracellular signal-regulated kinase (ERK)1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280, 19516-19526.
58. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, et al. (2004). Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516.
59. 2A receptor stimulation increases angiogenesis by downregulating production of the anti-angiogenic matrix protein thrombospondin 1 (TSP1). Mol Pharmacol 67, 1406-1413.
60. Salnikow K, Kluz T, Costa M, Piquemal D, Demidenko ZN, Xie K, and Blagosklonny MV (2002). The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia. Mol Cell Biol 22, 1734-1741.
61. Giaccia A, Siim BG, and Johnson RS (2003). HIF-1 as a target for drug development. Nat Rev Drug Discov 2, 803-811.
62. 2A receptors. Annu Rev Immunol 22, 657-682.
63. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, and Giannakakou P (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375.